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Summary points  
• By tradition colloids are used to obtain fast circulatory stabilisation in critically ill in general, and 
the use of hydroxyethyl starch (HES) may be supported by meta-analyses 
• High molecular weight HES may, however, cause acute kidney failure in patients with severe 
sepsis 
• Now the low molecular weight HES 130/0.4 is the preferred colloid in Scandinavian intensive 
care units (ICU) and 1st choice fluid for patients with severe sepsis 
• HES 130/0.4 is largely unstudied in patients with severe sepsis 
• The proposed Scandinavian multicentre trial will be conducted to assess the effects of HES 
130/0.4 on mortality and end-stage kidney failure in patients with severe sepsis 
• The trial will provide important data to all clinicians who resuscitate septic patients 
 
Background 
Fluid is the mainstay treatment for resuscitation of patients with severe sepsis. By tradition, colloids 
have been used to obtain fast circulatory stabilisation, but there are only few trials with patient-
centred outcome measures on fluid resuscitation of septic patient. The Surviving Sepsis Campaign 
recommends either colloids or crystalloids (1), but high molecular weight hydroxyethyl starch 
(HES) may cause acute kidney failure (AKF) in patients with severe sepsis as observed in a recent 
meta-analysis (2). The three largest trials in this analysis studied HES 200/0.6 (MW in 
kDa/substitution ratio - hydroxyethyl groups per glucose), but found divergent results with respect 
to kidney failure with this starch (3, 4, 5). All these trials had methodological weaknesses (6, 7), 
and two large cohort studies in ICU patients also showed divergent results with respect to the risk 
of adverse renal effects of starch treatment (8, 9). 
 
If HES contributes to AKF in severe sepsis, this is of importance as AKF is an independent risk 
factor for death in these patients (10, 11, 12, 13). And if AKF progress to end-stage kidney 
disease, prolonged renal replacement therapy will inflict burden to patients and society. 
 
High molecular weight HES also causes coagulopathy and bleeding and increase the rate of 
transfusion during major surgery (14), but effects in ICU patients are largely unstudied. 
 
Two Cochrane meta-analyses have been published on colloid use in critically ill in general. One 
compared colloids with crystalloids (15), but there were few trials on HES, so reliable conclusions 
cannot be drawn. The other analysis included a comparison between albumin and high molecular 
weight HES. In this, a relative risk reduction (RRR) greater than 20% could be rejected, but the 
observed 14% RRR with the use of HES could not (16). As the effects of albumin and crystalloids 
are likely to be equal (15), an alternative hypothesis may be that high molecular weight HES 
reduces the risk of death by 10 – 20% compared to crystalloids. 
 
However the high molecular weight HES is hardly ever used in Scandinavian ICUs, where HES 
130/0.4 is the preferred colloid (17) and 1st choice fluid for patients with severe sepsis (preliminary 
data from the SAFE TRIP study, S Finfer, personal communication, and the East Danish Septic 
Shock Cohort, A Perner, personal communication). 
 
Presently there are very limited data on the effects of HES 130/0.4 in ICU patients. To our 
knowledge only a single study has been published, in which 20 septic patients were randomised to 
fluid resuscitation with HES 130/0.4 or albumin (18). As for the effects on coagulation and 
bleeding, these may be less pronounced for HES 130/0.4 compared to HES 200/0.6, but this has 
only been shown perioperatively (14). 
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Taken together, two hypotheses can be put forward. Resuscitation with high molecular weight HES 
may cause AKF in patients with severe sepsis, or may improve survival by up to 20% when 
compared to crystalloids. In any case, the low molecular weight HES 130/0.4 widely used is largely 
unstudied in septic patients. Therefore, there is an urgent need for trials on HES 130/0.4 in sepsis. 
 
Aims 
To assess the effects of HES 130/0.4 compared with a balanced crystalloid solution on mortality 
and end-stage kidney failure in patients with severe sepsis. 
 
Design 
Multicentre, randomised, double-blinded trial with concealed allocation of septic patients 1:1 to fluid 
resuscitation using 6% HES 130/0.4 in Ringers acetate (Tetraspan, B Braun Medical) or Ringers 
acetate (Ringerfundin, B Braun Medical) stratified by the presence of shock or not (8), 
haematologic malignancy or not (8) and inclusion in a university hospital or not. 
 
Tetraspan 
Tetraspan contains hydroxyethylated starch 60 mg 130/0.42 per ml and the isotonic electrolyte 
solution of sodium chloride, potassium chloride, calcium chloride, magnesium chloride, sodium 
acetate and malic acid. It is marketed for the indication ‘treatment of imminent or manifest 
hypovolaemia and shock’ in all the Nordic countries (Summary of Product Characteristics for 
Tetraspan 6%, B Braun Medical). 
 
Ringerfundin 
Ringerfundin contains the isotonic electrolyte solution of sodium chloride, potassium chloride, 
calcium chloride, magnesium chloride, sodium acetate and malic acid. It is marketed for the 
indication ‘treatment of extracellular fluid loss by isotonic dehydration associated with manifest or 
imminent acidosis’ in all the Nordic countries (Summary of Product Characteristics for 
Ringerfundin, B Braun Medical). 
 
Inclusion 
All adult patients who 
• Undergo resuscitation in the ICU  
 
• AND fulfilment within the previous 24 hours of the criteria for severe sepsis according to the 
Society of Critical Care Medicine/American College of Chest Physicians (SCCM/ACCP), see 
Appendix 1 (19) 
 
• AND consent is obtainable either from the patient or by proxy (physician and/or next of kin) 
 
The following patients will not be evaluated for inclusion: 
• Age < 18 years 
• Previously randomised in the 6S trial 
• Allergy towards hydroxyethyl starch or malic acid 
• Treatment with > 1000 ml’s of any synthetic colloid within the last 24 hours prior to 
randomisation 
• Any form of renal replacement therapy 
• Acute burn injury > 10% body surface area 
• Severe hyperkalaemia, p-K > 6 mM  
• Liver or kidney transplantation during current hospital admission 
• Intracranial bleeding within current hospitalisation 
• Enrolment into another ICU trial of drugs with potential action on circulation, renal function or 
coagulation 
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• Withdrawal of active therapy 
 
Randomisation 
Staff at trial sites will have access to phone-based randomisation around the clock (CTU) to allow 
immediate and concealed allocation and treatment with trial fluid. Each patient will be given a 
unique patient-number and a randomisation number. 
 
Primary outcome measure 
The composite outcome measure of 90-day mortality or end-stage kidney disease defined as 
dialysis-dependency 90 days after randomisation (20) will be the primary outcome measure, and 
these two outcome measures will also be analysed separately. 
 
Secondary outcome measures 
• Twenty-eight-day, 6-month and 1-year mortality 
• Sepsis-related organ failure assessment (SOFA, modified from (21), see Appendix 5) score 
(excluding Glasgow Coma Score) at day 5 after randomisation 
• Kidney failure (SOFA score > 2 in the kidney component) at any time in the ICU after 
randomisation 
• Development of kidney failure (doubling of p-creatinine values) in the ICU after randomisation 
• Development of acidosis as the lowest recorded pHa in the ICU after randomisation 
• Need of dialysis/haemofiltration 
• Need of ventilation 
• Days alive without dialysis/haemofiltration in 90 days after randomisation  
• Days alive without ventilation in 90 days after randomisation 
• Hospital length of stay for survivors sanctioned at 90 days after randomisation 
 
Interventions 
Trial fluid is to be used for volume expansion during the entire ICU-stay for a maximum of 90 days. 
The treatment will follow the recommendations for fluid therapy given by the Surviving Sepsis 
Campaign, see Appendix 2 (1). The maximum dose of HES 130/0.4 recommended by the 
manufacturers is 50 ml/kg ideal BW/24 hours. The maximum dose of trial fluid will be 33 ml/kg 
ideal BW/24 hours as a recent retrospective study indicated that a dose of HES 130/0.4 above this 
might increase the risk of kidney failure in septic patients (22). After that unmasked treatment with 
Ringers acetate will be given to all patients. Maintenance fluids and nutrition should be given as 
clinically indicated. Blood products should be given for specific indications only as recommended 
by the Surviving Sepsis Campaign, see Appendix 2 (1). The treating clinicians will decide all other 
interventions. 
 
The following will be done to reduce the risk of giving too high doses of trial fluid: 
• The maximum daily dose of trial fluid will be based on estimated ideal body weight (men: 
estimated height in cm – 100; women: estimated height in cm – 105). 
• The calculated maximum daily dose of trial fluid will be reduced to the nearest 500 ml. 
• On the 1st day of the trial, any synthetic colloids given 24 hours prior to randomisation will be 
subtracted the calculated dose of trial fluid. 
 
If the patient is discharged and then readmitted to the ICU within 90 days of randomisation the 
allocated trial fluid must be used if volume expansion is indicated. 
 
Blinding 
The trial fluid is visually identical and will be delivered in identical 500 ml ‘flexibag’ plastic bottles, 
which will be put in black plastic bags and sealed by trial personnel not involved in randomisation 
or treatment of patients. A computer program (CTU) will generate the coding list with the numbers 
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for the bottle. At randomisation, the computer program (CTU) will allocate numbered bottles from 
the specific trial site to the patient. Each trial site will have sufficient number of bottles of trial fluid 
to be allocated to patients included. This will ensure that the patient is resuscitated only with the 
trial fluid that he/she was randomised to receive. 
 
Safety 
Patients will be withdrawn from the trial fluid-treatment protocol if 
• Renal replacement therapy is commenced for acute kidney failure OR 
• SARs or SUSARs occur (see below) 
 
Patient withdrawn from the trial fluid-treatment protocol for the above reasons will receive open-
label saline or Ringers lactate for volume expansion for the remaining days of the 90-day study 
period. 
 
The treating clinician can withdraw a patient from the trial fluid-treatment protocol if 
• The clinical status of the patient requires open-label fluid treatment. 
 
The independent Data Monitoring and Safety Committee – DMSC – will recommend pausing or 
stopping the trial if 
• Group-difference in the primary outcome measure is found at the interim analysis 
• Group-difference in 28- or 90-day mortality is found at the interim analysis 
• Group-difference in SARs or SUSARs is found at the interim analysis 
• Results from other trials show clear benefit or harm with one of the trial fluids 
 
Serious adverse reactions 
The serious adverse reactions - SARs - described with the use of the trial fluids are allergic 
reactions (both) and bleeding (starch) (Tetraspan and Ringerfundin Summaries of Product 
Characteristics). The occurrence of these will be recorded daily on the eCRF during the ICU stay 
and compared for the two trial groups by the DMSC at the interim analysis. An independent 
statistician will prepare the data for this. During the trial, Sponsor will send a monthly report on the 
occurrence of SARs to the DMSC and a yearly report to the ethics committees. 
 
Suspected unexpected serious adverse reactions (SUSARs) will be defined as serious adverse 
reactions not described in the Summaries of Product Characteristics for Tetraspan and 
Ringerfundin. SUSARs will be reported by trial site investigators to Sponsor through the eCRF 
within 24 h. Sponsor will report any SUSARs within 7 days to the drug agency via EudraVigilance, 
to the DMSC, which may request the randomisation status of the patient, and to B. Braun Medical. 
During the trial, Sponsor will send a monthly report on the occurrence of SUSARs to the DMSC 
and a yearly report to the ethics committees. 
 
Serious adverse events (SAEs) will not be recorded as an entity, because the majority of septic 
ICU patients will experience SAEs during their critical illness. The SAEs will be captured in the 
secondary outcome measures. 
 
Patient withdrawal 
Patients who are withdrawn from the trial fluid-treatment protocol (see Safety) will be followed up 
and analysed as the remaining patients. 
 
Patients may be withdrawn from the trial at any time if consent is withdrawn by the person(s), who 
has given surrogate consent or by the patient. The person making the withdrawal will be asked for 
permission to use data obtained prior to withdrawal and to obtain data for the primary outcome 
measure. If this is achieved the patient will be included in the final analyses. If this person declines, 
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all data from that patient will be destroyed and a new patient will be randomised to obtain the full 
sample size. 
 
Patients who are transferred to another ICU will be withdrawn from the trial fluid-treatment protocol 
unless this new ICU is an active trial site. If so the allocated trial fluid will be used if volume 
expansion is indicated in the new ICU. In any case, patients that are transferred to another ICU will 
be followed up for the primary outcome measure. 
 
Statistics 
Analysis will be by intention-to-treat comparing the composite outcome measure of death or 
dialysis-dependency at 90 days in the two groups by chi-squared test and multiple logistic 
regression analysis adjusting for design and patient variables (stratification variables, age, 
diabetes, use of nephrotoxic drugs, previous renal dysfunction (‘normal’ p-creatinine > 100 µmol/l) 
(9), acute kidney failure at randomisation (kidney failure defining severe sepsis) (8) and SAPS II (9) 
and SOFA score (8) in the 24 h where randomisation was done (23). 
 
2 x 400 patients will be needed to show a 20% RRR in the composite outcome measure under the 
assumption of a mortality of 45% (estimated from mean mortality rates in the AT III meta-analysis 
(24), the two groups in VISEP (4) and unpublished data from East Danish Septic Shock Cohort, A 
Perner, personal communication) and dialysis-dependency of 5% at 90 days (12, 13), thus 50% for 
the composite outcome measure, an alpha of 0.05 (two-sided) and a power of 80%. Thus a 
reduction in the frequency of the composite outcome measure from 50% to 40% can be shown. 
 
An interim analysis will be performed after 400 patients. The DMSC will recommend that the trial is 
stopped if it finds a group-difference in primary outcome measure, mortality, SARs or SUSARs with 
p<0.001 (Haybittle-Peto criteria) or otherwise find that the continued conduct of the trial clearly 
compromises patient safety. 
 
Data registration 
Data will be entered into the electronic web-based (ExpertMaker) case record form (eCRF) from 
patient notes (source) by trial or clinical personnel under the supervision of the trial site 
investigators. From the eCRFs the trial database (CTU) will be established. Paper CRF will be 
used in case of technical difficulties with the eCRF. 
 
Technical specifications: 
The sponsor supplies a standard description of all laboratory units of measurement, which have 
influence on the data. To the extent that a centre uses different unit of measurement, it must 
submit a correction list to the data centre and the sponsor and, if necessary, have its data capture 
module modified accordingly. 
 
Pre-randomisation characteristics (all obtained from hospital notes): 
National identification number, sex, age at randomisation, estimated height in cm, co-morbidities 
(previously admitted for heart failure or myocardial infarction Y/N, previous admitted for stroke Y/N, 
chronic treatment for arterial hypertension Y/N, chronic treatment for diabetes Y/N, previously 
admitted for asthma or chronic obstructive pulmonary disease Y/N), haematological malignancy 
Y/N, from where was the patient admitted to the ICU? (Emergency ward / general ward / operation 
theatre or recovery / via paramedic or ambulance services / other ICU this hospital / other 
hospital), elective or emergency surgery within current hospital admission Y/N, site of infection 
(pulmonary/abdominal/urinary tract/soft tissue/other), and ‘normal’ p-creatinine. Use of potential 
nephrotoxic drugs (Y/N) during current hospital admission: Gentamycin, vancomycin, Amphotericin 
B, polymyxins, ciclosporin A, IV contrast dye, NSAIDs and Cox-2 inhibitors. 
 
24-hours prior to randomisation: 
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• Values for simplified acute physiology score (SAPS) II (25) 
• Parameters for SOFA scoring not covered above: Lowest mean arterial blood pressure value 
and highest infusion rate of vasoactive drugs 
• Volume of resuscitation fluids (crystalloids, colloids and blood products specified in ml) 
• Results of blood samples (standard lab. values) for haemoglobin (lowest value), bilirubin 
(highest value), INR (highest value), d-dimer (highest value) and platelets (lowest value). 
 
At randomisation (+/- 2 hours): 
• Lowest values of mean arterial blood pressure, central venous pressure, central venous 
oxygen saturation and highest values of arterial or venous lactate concentration obtained from 
the ICU charges 
 
12-hourly in the first 24 after randomisation: 
• Highest and lowest values of central venous pressure, central venous oxygen saturation and 
arterial or venous lactate concentration obtained from the ICU charges 
 
Daily in the first 5 days after randomisation: 
• Results of morning samples of bilirubin, INR and platelets (standard lab. values). 
• Parameters for daily SOFA scoring not covered above: Lowest blood pressure value and 
highest infusion rate of vasoactive drugs and lowest ratio of arterial oxygen tension/fraction of 
inspired oxygen obtained from the ICU charges 
 
During the entire ICU stay: 
• Daily volumes of trial fluid and other fluids incl. blood products, nutrition, total fluid input, urinary 
output and calculated fluid balance as of the ICU charges 
• Daily lowest values of blood haemoglobin and arterial pH and standard base excess (point of 
care testing) and highest value of p-creatinine (standard lab. value) 
• On mechanical invasive- or non-ventilation (as marked in the SOFA scoring day 0-5 and Y/N at 
08.00 from day 6) 
• Any use of potential nephrotoxic drugs as mentioned above (Y/N for every day) 
• Bleeding episodes noted in patient files including gastrointestinal (haematemesis, frank blood 
or "coffee grounds" in a nasogastric aspirate, or melaena or frank blood in stools), wounds, 
during surgery or frank blood in urine or tracheal aspirates. 
• Serious adverse reactions (Y/N for every day) including severe bleeding (intracranial bleeding 
or bleeding episode (defined as above) with the need for > 3 units of blood per day (defined as 
the 24 h of the units fluid charge)) or serious allergic reactions defined as urticaria associated 
with worsened circulation (20% decrease in blood pressure or 20% increase in vasopressor 
dose), increased airway resistance (20% increase in the peak pressure on the ventilation or 
clinical stridor or bronchospasme or treatment with bronchodilators). 
 
90 days after randomisation: 
• Survival status obtained from hospital or civil registries 
• If the patient is deceased, date of death 
• Dialysis-dependency at day 90 defined as need of a dialysis treatment session within the time 
period 4 days prior to or after day 90 post-randomisation as obtained from hospital notes or 
registries. 
• Total days of dialysis-dependency (haemo-dialysis or –filtration) summarised at day 90 from 
hospital notes or registries. First and last treatment session will define length of dialysis-
dependency in each patient. 
• Date of hospital discharge as obtained from hospital notes or registries 
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½- and 1 year after randomisation: 
• Survival status obtained from hospital or civil registries 
 
Data handling and retention 
Data will be handled according to the data protection agencies of the different countries. All original 
records (incl. consent forms, CRFs, SAR reports and relevant correspondences) will be retained at 
trial sites or CTU for 15 years to allow inspection by the GCP Unit or local authorities. The study 
database will be maintained for 15 years and anonymised if requested by the authorities. 
 
Monitoring 
The trial will be externally monitored (the GCP unit at University of Copenhagen) to GCP standards 
according to the EU directive 2001/20. Trial site investigators will give access to source data 
according to the Clinical Trial Agreement. 
 
Ethics 
The trial will adhere to the Helsinki Declaration II and the national laws in the Nordic countries. 
Inclusion will start after approval by the ethical committees, drug agencies and data protection 
agencies in the country of the trial site and trial registration at www.clinicaltrials.gov. 
 
Patients will only be enrolled after informed consent, but the treatment has to be initiated 
immediately and most patients will be unconscious and therefore included after proxy consent 
(physician and/or next of kin) according to national laws. The patient or the patient next of kin 
and/or general practitioner will be asked for delayed consent if required by national law. 
 
The trial cannot be performed in conscious persons, as no clinically relevant model of severe 
sepsis exists and no conscious patients have the combination of severe infection and multiple 
organ failure as septic patients have. 
 
No biological material will be collected for the trial, thus no bio-bank will be formed. 
 
Enrolment 
Patients are expected to be included from 25 Scandinavian ICUs (Denmark 10 units, Sweden 10, 
Norway 2, Finland 2 units and Iceland 1 unit) during a 2-year period starting November 2009. In a 
previous study (SAFE TRIPS) we have enrolled patients from 63 Scandinavian ICUs. 
Each of the 25 units has to include 2 patients per month (holidays excluded) to finish inclusion in 2 
years. Unpublished data from East Danish Septic Shock Cohort (A Perner, personal 
communication) indicate that Danish ICUs treat 5 - 15 patients with septic shock per month. The 
number of patients with severe sepsis or septic shock will be higher making it realistic to include an 
average of 2 patients per ICU per month. 
 
Data analyses and publications 
An independent statistician will perform the data analysis prior to the breaking of the randomisation 
code. Based on these masked analyses of the primary and secondary outcome measures two 
abstracts will be written by the Writing Committee, the randomisation code will then be opened and 
a final manuscript written containing the correct of the two pre-made abstracts. The manuscript will 
be submitted to one of the major clinical journals regardless of the results. The Steering committee 
will grant authorship depending on personal input (see Appendix 4) according to the Vancouver 
definitions. All trial sites and trial site investigators will be acknowledged. Funding sources will have 
no influence on data handling or analysis or writing of the manuscript. 
Side studies will be allowed if supported by the Steering committee. 
 
Timeline 
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2008 - 2009: Applications for funding, ethical committees and drug agencies, development of 
CRFs and data management tools and development of monitoring plan and education of monitors 
2009 - 2011: Inclusion of patients 
2010: Interim analysis 
2011: Data analysis, writing of a manuscript and publication 
 
Tasks and responsibilities 
Principle Investigator (PI) and ‘Sponsor’: Anders Perner 
 
Trial Steering and Management Committee: The national investigators, Nicolai Haase (PhD 
student at Rigshospitalet and CTU) and Jørn Wetterslev (CTU) will apply for funding and ethical 
and drug agency approvals and will recruit and manage trial sites in their countries. 
 
Trial Site Investigators will be responsible for all trial-related procedures at their site including trial 
fluid, education of staff in trial-related procedures, recruitment and follow-up of patients and entry 
of data. Clinical staff at the trial sites will do the treatment of trial patients. 
 
Independent Data Monitoring and Safety Committee: Daniel De Backer (chair), Peter Dalgaard and 
Kathy Rowan will evaluate SUSARs and the interim analyses and will provide recommendations 
about stopping or continuing the trial to the Steering Committee of the trial, see Charter for the 
DMSC, Appendix 3. 
 
Collaborators 
Copenhagen Trial Unit, Centre for Clinical Intervention Research, Rigshospitalet will develop the 
CRF together with the Steering Committee and systems for phone-based randomisation, allocation 
of trial fluid and data handling. 
 
The GCP unit at University of Copenhagen will develop the monitoring plan, educate monitors and 
coordinate monitoring in cooperation with the GCP units in Aarhus, Lund and Oslo. Together these 
units will cover all trial sites in all countries. 
 
The Scandinavian Society of Anaesthesia and Intensive Care will provide the platform for web-
based data entry - the eCRF (Expertmaker AB). 
 
B Braun Medical AG (Melsungen, Germany) will delivery trial fluids to all trial sites. 
 
Finances 
The Danish research council support the trial for 2009 - 2012 (1,2 mill Dkr.). Public and private 
funds will be applied for the remaining budget. 
 
Insurance 
The patients will be covered by the insurance of the trial sites. 
 
Perspective 
Severe sepsis affects millions of patients worldwide with high rates of complications and mortality. 
Outcome differences between therapies for severe sepsis will, therefore, have major impact on 
global health and healthcare costs. 
 
Currently, two other RCTs are assessing the effect of HES 130/0.4 in sepsis: 
BASES is a single centre study expected to include 250 patients with severe sepsis. The primary 
outcome measure is ICU length of stay, but biochemical markers of kidney failure and the 
frequency of renal replacement therapy is also recorded (clinicaltrial.gov identifier: NCT00273728). 
Inclusion is expected to be completed in May 2010 (M Siegemund, personal communication). 
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CRYSTMAS is a multicentre study expected to include 200 patients with severe sepsis. The 
primary outcome measure is amount of fluid required to achieve initial haemodynamic stabilisation 
and amount of enteral calories given in the 7 days after stabilisation. Biochemical markers of 
kidney failure will also be recorded. Inclusion is expected to be completed in April 2010 
(clinicaltrial.gov identifier: NCT00464204). 
 
In addition, an Australian/New Zealand multicentre RCT is planned to compare HES 130/0.4 and 
saline in 7,000 hypovolaemic ICU patients (NCT00935168). The primary outcome measure will be 
90-day mortality and subgroup analysis of patients with severe sepsis is planned (J Myburgh, 
personal communication). We collaborate with the investigators and plan a common individual 
patient data meta-analysis combining our data with those of their patients with severe sepsis. Thus 
in- and exclusion criteria and outcome measures of the two trials have been aligned to prepare for 
the common analysis. 
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Appendix 1 
 
Trial criteria for severe sepsis 
 
SEPSIS is defined as a (1) DEFINED FOCUS OF INFECTION AND (2) at least TWO systemic 
inflammatory response syndrome (SIRS) criteria. 
 
(1) DEFINED FOCUS OF INFECTION is indicated by either  
(i) An organism grown in blood or sterile site  
OR 
(ii) An abscess or infected tissue (e.g. pneumonia, peritonitis, urinary tract, vascular line infection, 
soft tissue, etc). 
 
(2) The 4 SIRS criteria are: 
1. CORE TEMPERATURE >38°C or <36°C. (Core temperature is rectal, urinary bladder, 
central line, or tympanic). If oral, inguinal or axillary temperatures are used, add 0.5°C to 
the measured value. Hypothermia <36°C must be confirmed by core temperature only. Use 
the most deranged value recorded in the 24 hours before randomisation. 
2. HEART RATE >90 beats/minute. If patient had an atrial arrhythmia, record the ventricular 
rate. If patients have a known medical condition or are receiving treatment that would 
prevent tachycardia (for example, heart block or beta blockers), they must meet two of the 
remaining three SIRS criteria. Use the most deranged value recorded in the 24 hours 
before randomisation. 
3. RESPIRATORY RATE > 20 breaths per minute or a PaCO2 < 4.3 kPa (32 mmHg) or 
mechanical ventilation for an acute process. Use the most deranged respiratory rate or 
PaCO2 recorded in the 24 hours before randomisation. 
4. WHITE BLOOD CELL COUNT of >12 x 109/l or < 4 x 109/l or > 10% immature neutrophils 
(band forms). Use the most deranged value recorded in the 24 hours before randomisation. 
 
SEVERE SEPSIS is defined as SEPSIS plus at least ONE ORGAN FAILURE, except when that 
organ failure was already present 48 hours before the onset of sepsis. 
 
ORGAN FAILURE is defined as a Sequential Organ Failure Assessment (SOFA) score > 2 for the 
organ in question, see Appendix 5.
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Appendix 2 
The Surviving Sepsis Campaigns recommendations (1) 
 
For fluid therapy 
 
• Use a fluid challenge technique while associated with a haemodynamic improvement 
• Give fluid challenges of 500 - 1000 ml over 30 min. More rapid and larger volumes may be 
required in sepsis-induced tissue hypoperfusion 
• Rate of fluid administration should be reduced if cardiac filling pressures increase without 
concurrent haemodynamic improvement 
 
 
For endpoints of resuscitation in the first 6 hours of severe sepsis or septic shock 
 
• Central venous pressure: 8–12 mm Hg* 
• Mean arterial pressure > 65 mm Hg 
• Urine output  > 0.5 ml/kg/h 
• Central venous (superior vena cava) or mixed venous oxygen saturation ScvO2 / SvO2 > 70% 
 
If venous O2 saturation target is not achieved: 
– consider further fluid 
– transfuse packed red blood cells if required to haematocrit of ≥ 30% and/or  
– dobutamine infusion max 20 µg/kg/min 
 
*A higher target CVP of 12–15 mm Hg is recommended in the presence of mechanical ventilation 
or pre-existing decreased ventricular compliance. 
 
 
For administration of blood products 
 
• Give red blood cells when haemoglobin decreases to < 7.0 g/dl (< 4.5 mM) to target 
haemoglobin of 7.0 - 9.0 g/dl  (4.5 – 5.6 mM). A higher haemoglobin level may be required in 
special circumstances (e.g.: myocardial ischaemia, severe hypoxaemia, acute haemorrhage, 
cyanotic heart disease or lactic acidosis) 
• Do not use fresh frozen plasma to correct laboratory clotting abnormalities unless there is 
bleeding or planned invasive procedures 
• Administer platelets when 
– counts are < 5 × 109/l regardless of bleeding 
– counts are 5 - 30 × 109/l and there is significant bleeding risk 
– higher platelet counts (≥ 50 × 109/l) are required for surgery or invasive procedures 
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Appendix 3 
 
Charter for the independent Data Monitoring and Safety Committee (DMSC) of the 
6S trial. 
 
EudraCT no. 2009-010104-28 Clinical Trial no. NCT00962156. 
 
Copenhagen 2009 
 
Introduction 
The Charter will define the primary responsibilities of the DMSC, its relationship with other trial 
components, its membership, and the purpose and timing of its meetings. The Charter will also 
provide the procedures for ensuring confidentiality and proper communication, the statistical 
monitoring guidelines to be implemented by the DMSC, and an outline of the content of the Open 
and Closed Reports that will be provided to the DMSC. 
    
Primary responsibilities of the DMSC 
The DMSC will be responsible for safeguarding the interests of trial participants, assessing the 
safety and efficacy of the interventions during the trial, and for monitoring the overall conduct of the 
clinical trial. The DMSC will provide recommendations about stopping or continuing the trial to the 
Steering Committee (SC) of the 6S trial. To contribute to enhancing the integrity of the trial, the 
DMSC may also formulate recommendations relating to the selection/recruitment/retention of 
participants, their management, improving adherence to protocol-specified regimens and retention 
of participants, and the procedures for data management and quality control. 
 
The DMSC will be advisory to the SC. The SC will be responsible for promptly reviewing the DMSC 
recommendations, to decide whether to continue or terminate the trial, and to determine whether 
amendments to the protocol or changes in trial conduct are required. 
 
Members of the DMSC 
The DMSC is an independent multidisciplinary group consisting of clinicians and a biostatistician 
that, collectively, has experience in the management of ICU patients and in the conduct, 
monitoring and analysis of randomised clinical trials. 
 
DMSC Clinician 
Dr. Daniel De Backer, Dept. of Intensive Care, Erasme University Hospital, Brussels 
 
DMSC Clinical trialist 
Prof. Kathy Rowan, Intensive Care National Audit and Research Center (ICNARC), London 
 
DMSC Biostatistician 
Dr. Peter Dalgaard, Dept. of Biostatistics, University of Copenhagen  
 
Conflicts of interest 
DMSC membership has been restricted to individuals free of conflicts of interest. The source of 
these conflicts may be financial, scientific, or regulatory in nature. Thus, neither trial investigators 
nor individuals employed by the sponsor, nor individuals who might have regulatory responsibilities 
for the trial products, are members of the DMSC. The DMSC members do not own stock in the 
companies having products being evaluated by the 6S trial.  
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The DMSC members will disclose to fellow members any consulting agreements or financial 
interests they have with the sponsor of the trial, with the contract research organisation (CRO) for 
the trial (if any), or with other sponsors having products that are being evaluated or having 
products that are competitive with those being evaluated in the trial.  
 
The DMSC will be responsible for deciding whether these consulting agreements or financial 
interests materially impact their objectivity. 
 
The DMSC members will be responsible for advising fellow members of any changes in these 
consulting agreements and financial interests that occur during the course of the trial. Any DMSC 
members who develop significant conflicts of interest during the course of the trial should resign 
from the DMSC.  
 
DMSC membership is to be for the duration of the clinical trial. If any members leave the DMSC 
during the course of the trial, the SC will appoint the replacement(s). 
 
Formal interim analysis meeting 
One 'Formal Interim Analysis' meeting will be held to review data relating to treatment efficacy, 
patient safety, and quality of trial conduct. The three members of the DMSC will meet when 90-day 
follow-up data of 400 patients have been obtained. 
 
Proper communication 
To enhance the integrity and credibility of the trial, procedures will be implemented to ensure the 
DMSC has sole access to evolving information from the clinical trial regarding comparative results 
of efficacy and safety data, aggregated by treatment group (0,1). An exception will be made to 
permit access to an independent statistician who will be responsible for serving as a liaison 
between the database and the DMSC.  
 
At the same time, procedures will be implemented to ensure that proper communication is 
achieved between the DMSC and the trial investigators. To provide a forum for exchange of 
information among various parties who share responsibility for the successful conduct of the trial, a 
format for Open Sessions and Closed Sessions will be implemented. The intent of this format is to 
enable the DMSC to preserve confidentiality of the comparative efficacy results while at the same 
time providing opportunities for interaction between the DMSC and others who have valuable 
insights into trial-related issues. 
 
Closed Sessions 
Sessions involving only DMSC membership who generates the Closed Reports (called Closed 
Sessions) will be held to allow discussion of confidential data from the clinical trial, including 
information about the relative efficacy and safety of interventions. In order to ensure that the 
DMSC will be fully informed in its primary mission of safeguarding the interest of participating 
patients, the DMSC will be blinded in its assessment of safety and efficacy data. However, the 
DMSC can request unblinding from the SC. 
 
Open Reports 
For each DMSC meeting, Open Reports will be provided available to all who attend the DMSC 
meeting. The Reports will include data on recruitment and baseline characteristics, and pooled 
data on eligibility violations, completeness of follow-up, and compliance. The primary trial 
statistician will prepare these Open Reports. 
 
Closed Reports will include analysis of the primary efficacy outcome measure. In addition, 
analyses of the secondary outcome measures and serious adverse events will also be reported. 
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These Closed Reports will be prepared by an independent biostatistician, with assistance from the 
trial biostatisticians, in a manner that allow them to remain blinded. 
 
The Closed Reports should provide information that is accurate, with follow-up on mortality that is 
complete to within two months of the date of the DMSC meeting. 
  
The Reports should be provided to DMSC members approximately three days prior to the date of 
the meeting. 
 
Minutes of the DMSC Meetings 
The DMSC will prepare minutes of their meetings. The Closed Minutes will describe the 
proceedings from all sessions of the DMSC meeting, including the listing of recommendations by 
the Committee. Because it is likely that these minutes may contain unblinded information, it is 
important that they are not made available to anyone outside the DMSC.  
 
Recommendations to the Steering Committee  
After the interim analysis meeting, the DMSC will make a recommendation to the SC to continue, 
hold or terminate the trial. 
 
This recommendation will be based primarily on safety and efficacy considerations and will be 
guided by statistical monitoring guidelines defined in this Charter and the trial protocol. 
 
The SC is jointly responsible with the DMSC for safeguarding the interests of participating patients 
and for the conduct of the trial. Recommendations to amend the protocol or conduct of the trial 
made by the DMSC will be considered and accepted or rejected by the SC. The SC will be 
responsible for deciding whether to continue, hold or stop the trial based on the DMSC 
recommendations.  
The DMSC will be notified of all changes to the trial protocol or conduct. The DMSC concurrence 
will be sought on all substantive recommendations or changes to the protocol or trial conduct prior 
to their implementation. 
 
Statistical monitoring guidelines 
The outcome parameters are defined in the 6S trial protocol. 
 
For the two intervention groups, the DMSC will evaluate data on: 
 
The primary outcome measure 
The composite outcome measure of death or dialysis-dependency 90 days after randomisation 
analysed together and separately 
 
The secondary outcome measures 
28-day mortality 
Severity organ failure assessment (SOFA) score at day 5 after randomisation 
Kidney failure (SOFA score >2 in the kidney component) during the ICU stay 
Need of dialysis 
Days free of dialysis for survivors 
Serious adverse reactions - SARs - (severe allergic reactions or severe bleeding) and suspected 
unexpected serious adverse reactions - SUSARs 
 
The DMSC will be provided with these data from the Coordinating Centre as: 
a. Number of patients randomised 
b. Number of patients randomised per intervention group (0,1) 
c. Number of patients stratified pr. stratification variable per intervention group (0,1) 
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d. Number of events, according to the outcomes, in the two groups 
 
Based on evaluations of these outcomes, the DMSC will decide if they want further data from the 
Coordinating Centre and when next to perform analyses of the data. 
 
For analyses, the data will be provided in one file as described below. 
 
Based on the analyses of the primary outcome measure and SARs, the DMSC will use P<0.001 
(Haybittle-Peto) as the statistical limit to guide its recommendations regarding early termination of 
the trial.  
 
Based on 28- and 90-day mortality analyses, the DMSC will use P<0.001 (Haybittle-Peto) and 
group sequential monitoring boundaries as the statistical limit to guide its recommendations 
regarding early termination of the trial. 
 
DMSC should also be informed about all SUSARs and SARs occurring in the two groups of the 
trial. 
 
The DMSC may also be asked to ensure that procedures are properly implemented to adjust trial 
sample size or duration of follow-up to restore power, if protocol specified event rates are 
inaccurate. If so, the algorithm for doing this should be clearly specified. 
 
 
Conditions for transfer of data from the Coordinating Centre to the DMSC  
The DMSC shall be provided with the data described below in one file. 
 
The DMSC will be provided with an Excel database containing the data defined as follows: 
 
1. Row 1 contains the names of the variables (to be defined below). 
 
2. Row 2 to N (where N-1 is the number of patients who have entered the trial) each contains the 
data of one patient. 
 
3. Column 1 to p (where p is the number of variables to be defined below) each contains in row 1 
the name of a variable and in the next N rows the values of this variable. 
 
 
The values of the following variables should be included in the database: 
 
1: PtID: a number that uniquely identifies the patient. 
 
2: Rdcode: The randomisation code (group 0 or 1) – the DMSC is not to be informed on what 
intervention the groups received. 
 
3. 1.EndInd: Primary outcome measure indicator (1 if patient fulfilled the primary outcome measure 
at day 90 and 0 if the patient did not). 
 
4: 90MInd: 90 day-mortality indicator (2 if patient is censored, 1 if patient was dead, and 0 if the 
patient was alive at day 90). 
 
5: 90DIAInd: Dialysis dependency at day 90 (2 if patient is censored, 1 if patient is dependent, and 
0 if the patient is not). 
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6: 28MInd: 28 day-mortality indicator (2 if patient is censored, 1 if patient is dead, and 0 if the 
patient is known to be alive). 
 
7: SOFAInd: SOFA indicator (SOFA score of the patient at day 5). 
  
8: AKFInd: Acute kidney failure indicator (1 if patient had kidney failure during the ICU stay, 0 if the 
patient did not). 
 
9: DIAInd: Dialysis indicator (1 if patient needed any dialysis from randomisation till day 90 and 0 if 
the patient did not). 
 
10: DiaDInd: Days free of dialysis indicator (no. of day from randomisation till day 90 free of 
dialysis for each patient; 0 if the patient did not need dialysis; blank if the patient had died). 
 
11: SARInd: Serious Adverse Reaction indicator (1 if patient has had a SAR during ICU stay and 0 
if the patient did not). 
 
12: SUSARInd: Suspected Unexpected Serious Adverse Reaction indicator (1 if patient has had a 
SUSAR during ICU stay and 0 if the patient did not).
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Appendix 4 
 
Acknowledgment of academic contribution and authorship 
All trial sites including patients will be acknowledged, and all investigators at these sites will appear 
with their names under ‘the 6S trial investigators’ in an Appendix to the final manuscript. 
 
The Steering Committee will grant authorship depending on personal involvement according to the 
Vancouver definitions. If a trial site investigator is to gain authorship, the site has to include 30 
patients or more. If the site includes 60 patients or more, two authorships will be granted. 
 
The listing of authors will be as follows: A Perner will be the first author, N Haase the second and 
the next authors will be the other members of the Steering Committee according to the number of 
included patients per country, then trial site investigators dependent on the number of included 
patients per site, J Wetterslev will appear as the last author and then ‘for the 6S trial investigators’. 
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Appendix 5 
 
SOFA scoring (ex. GCS) - use the most deranged value recorded in the previous 24 h (21) 
 
ORGAN SYSTEM 0 1 2 3 4 Organ scores 
Respiration      
 
PaO2 / FiO2  (in 
mmHg) >400 301 - 400 
<301 (without 
respiratory support*) 
101 - 200 
(with respiratory 
support*) 
≤ 100 
(with respiratory 
support*) 
(in kPa) >53 40 – 53 <40 (without 
respiratory support*) 
13 – 27 
(with respiratory 
support*) 
≤ 13 
(with respiratory 
support*) 
Coagulation 
Platelets (x 109 / l) >150 101 - 150 51 – 100 21 - 50 ≤ 20  
Liver      
 
Bilirubin (mg / dl) < 1.2 1.2 – 1.9 2.0 – 5.9 6.0 – 11.9 > 12.0 
                   (µmol / l) <20 20 - 32 33 – 101 102 - 204 >204 
Cardiovascular 
Hypotension  MAP > 70 mmHg MAP < 70 mmHg 
dopamine ≤ 5.0 
(doses are given in µg 
/ kg / minute)  
dopamine > 5.0 
(doses are given in µg 
/ kg / minute) 
dopamine > 15.0  
(doses are given in µg 
/ kg / minute) 
 
   
or any dose 
dobutamine or adrenalin ≤ 0.1 or adrenalin >0.1 
   
or any dose milrinone 
or any dose 
levosimendan 
or noradrenalin ≤ 0.1 
or any dose 
vasopressin 
or any dose 
phenylephrine  
or noradrenalin >0.1 
Renal 
Creatinine (mg / dl) 
 
< 1.2 
 
1.2 – 1.9 
 
2.0 – 3.4 
 
3.5 – 4.9 
 
> 5.0 
 
                         
(µmol/l) < 110 110 – 170 171 – 299 300 – 440 > 440 
OR Urine output 
   or < 500 ml / day or < 200 ml / day 
If a value has not been measured, the score 0 should be given 
*Respiratory support is defined as any form of invasive or non-invasive ventilation including mask CPAP or CPAP delivered through a tracheotomy 
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6S-trial - Original Statistical Analysis Plan 
 
 
Populations 
 
Intention-to-treat: All randomised patients. This population is not analysed in the 6S-trial. 
 
Modified intention-to-treat:  
All randomised patients except patients who  
- were not eligible for randomisation according to the 
inclusion/exclusion criteria 
AND 
- who never had any of the interventions (masked trial fluid). 
 
 
Per-protocol #1:  
All randomised patients except patients having one or more major protocol violations 
defined as 
- Patients who were not eligible for randomisation according to the 
inclusion/exclusion criteria. 
OR 
- Patients who never had the intervention (masked trial fluid). 
OR 
- Patients who accidentally received wrong intervention (intervention 
error). 
OR 
- Patients who received any synthetic colloid after randomisation. 
OR 
- Patients who were withdrawn from the protocol because the proxy, 
the relatives, the general practitioner or the patient himself withdrew 
consent. 
 
Per-protocol #2:  
All randomised patients except patients having one or more major protocol violations 
defined as 
- Patients who were not eligible for randomisation according to the 
inclusion/exclusion criteria. 
OR 
- Patients who never had the intervention (masked trial fluid). 
OR 
- Patients who accidentally received wrong intervention (intervention 
error). 
OR 
- Patients in the Ringer’s acetate arm, who received any synthetic 
colloid after randomisation. 
OR 
- Patients who were withdrawn from the protocol because the proxy, 
the relatives, the general practitioner or the patient himself withdrew 
consent. 
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Subgroups:  
- Patients where renal failure define severe sepsis (renal component 
of SOFA-score = 2 OR higher) 
- Patients with shock at time of randomisation (mean arterial pressure 
< 70 mmHg after the initial fluid resuscitation OR ongoing treatment 
with noradrenalin, adrenalin, dopamin, dobutamin, vasopressin, 
phenylephrine, milrinone or levosimendan OR arterial or venous 
lactate > 4.0 mmol/L within the last hour) 
 
 
Analyses 
 
Primary analysis: 
 
Unadjusted Chi-square test for binary outcome measures. For rate data the 
generalized linear model (SAS proc genmod) will be used with distribution Poisson, link=log and 
offset. 
 
 
Secondary analysis (will only be made for the modified intention-to-treat population): 
 
Multiple (logistic) regression and analysis of rate data with the following covariates: 
 
Binary covariates 
- Center is a university hospital Y/N (stratification variable) 
- Diagnose of hematological malignancy at time of randomisation Y/N 
(stratification variable) 
- Shock at time of randomisation Y/N (as defined above) (stratification 
variable) 
- Diabetes at time of randomisation Y/N 
- Use of nephrotoxic drugs during current admission and prior to 
randomisation Y/N 
- Previous renal dysfunction (‘normal’ creatinine >100 µmol/l = 
baseline variable #2) Y/N 
- Acute Kidney Failure at randomisation (renal failure defining severe 
sepsis as defined above) 
 
Continuous covariate 
- Age 
 
Ordinal covariates 
- SAPS II 
- SOFA-score 
 
 
Outcomes 
 
Primary outcome measure 
The composite outcome measure of 90-day mortality or end-stage kidney disease defined as 
dialysis-dependency 90 days after randomisation (+/- 4 days) as retrieved from the National 
Patient Hospital Register and the National Dialysis Database. 
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These two outcome measures will also be analysed separately. 
 
Secondary outcome measures 
• Twenty-eight-day, 6-month and 1-year mortality 
 
• Time to death or censoring 
 
• SOFA-score without cerebral component (see Appendix 5) on day 5 after randomisation. 
 
• Development of kidney failure defined as 
o Renal component of SOFA-score (renal-SOFA) = 3 or higher at any time in the ICU 
after randomisation, but renal-SOFA < 3 before randomisation (baseline values) 
OR 
o Patient requiring dialysis at any time after randomisation 
 
• Development of kidney failure at any time in the ICU after randomisation defined as 
o Doubling of p-creatinine values = 2 x ‘normal creatinine’ (baseline variable #2) 
 
• Development of acidosis (pHa < 7,35) in the ICU after randomisation 
o As data from day 1 may reflect baseline characteristics, the analysis will be made 
with and without day 1. 
 
• Need of dialysis/haemofiltration at any time after randomisation 
 
• Need of ventilation at any time after randomisation 
 
• Days alive without dialysis/haemofiltration in the 90 days after randomisation 
We define the value of a “period of dialysis” which runs from the day where dialysis is 
initiated till the day where the last dialysis is performed as the number of dates 
included in the period. The outcome measure is calculated as 90 days minus “the 
number of days in the period of dialysis” / 90 days. 
 
• Days alive without ventilation in 90 days after randomisation 
If the patient is on the ventilator at 8 am, the day is a ventilator-day. The outcome 
measure is calculated as 90 days minus the number of “ventilator days” / 90 days. 
 
• Hospital length of stay for survivors censored at 90 days after randomisation 
 
 
 
Level of statistical significance for all analyses: P = 0.05 
 
 
 
 
Missing Data 
 
Kidney failure at time of randomisation: If the patient doesn’t have kidney failure on day 1, this 
observation will be carried backward. 
 
 28 
‘Normal’ creatinine < 100 mmol/l: If the patient has any creatinine < 100 mmol/l without renal 
replacement therapy during or after the ICU-stay, the ‘normal’ creatinine will be considered < 100 
mmol/l.  
 
SOFA-score: There will be missing data for patients who  
- die before day 5 
OR  
- are discharged from the ICU before day 5 and are still alive on day 
5.  
 
Initially, we will perform a complete case-analysis. Then a supplementary analysis 
where patients who die before day 5 get the maximum score (20 points), and where 
patients who are discharged from the ICU and alive on day 5 will get 0 points.  
 
 For patients, who are still in the ICU on day 5, last observation will be carried forward. 
 
If the frequency of missing data after the above implemented “imputations” is > 5% and the 
complete case analysis is significant at the 10% value or less, we will perform an additional 
analysis using the multiple imputation method.  
 
 
To put significant results into perspective the following sensitivity analysis will be conducted: We 
define a worst case scenario as one where patients with missing data do not react on the 
treatment (whatever it may be). Missing data will be imputed according to this scenario. Let P be 
the estimate of the parameter reflecting the effect of the intervention calculated from the complete 
case analysis and P-imp be the corresponding estimate calculated from the analysis of the 
imputed data.  
[(P-imp – P)/P-imp]*100% then a ball park figure of the bias is to be expected were the worst case 
scenario true. 
P-imp/ (standard error of P-imp) is calculated and the corresponding p value found to assess the 
potential impact of this bias on the significance level.  
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6S-trial - Final Statistical Analysis Plan 
 
 
Populations 
 
Intention-to-treat: All randomised patients. This population is not analysed in the 6S-trial. 
 
Modified intention-to-treat:  
All randomised patients except patients who  
- were not eligible for randomisation according to the 
inclusion/exclusion criteria 
AND 
- who never had any of the interventions (masked trial fluid). 
 
 
Per-protocol #1:  
All randomised patients except patients having one or more major protocol violations 
defined as 
- Patients who were not eligible for randomisation according to the 
inclusion/exclusion criteria. 
OR 
- Patients who never had the intervention (masked trial fluid). 
OR 
- Patients who accidentally received wrong intervention (intervention 
error). 
OR 
- Patients who received any synthetic colloid after randomisation. 
OR 
- Patients who were withdrawn from the protocol because the proxy, 
the relatives, the general practitioner or the patient himself withdrew 
consent. 
 
Per-protocol #2:  
All randomised patients except patients having one or more major protocol violations 
defined as 
- Patients who were not eligible for randomisation according to the 
inclusion/exclusion criteria. 
OR 
- Patients who never had the intervention (masked trial fluid). 
OR 
- Patients who accidentally received wrong intervention (intervention 
error). 
OR 
- Patients in the Ringer’s acetate arm, who received any synthetic 
colloid after randomisation. 
OR 
- Patients who were withdrawn from the protocol because the proxy, 
the relatives, the general practitioner or the patient himself withdrew 
consent. 
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Subgroups:  
- Patients where renal failure define severe sepsis (renal component 
of SOFA-score = 2 OR higher) 
- Patients with shock at time of randomisation (mean arterial pressure 
< 70 mmHg after the initial fluid resuscitation OR ongoing treatment 
with noradrenalin, adrenalin, dopamin, dobutamin, vasopressin, 
phenylephrine, milrinone or levosimendan OR arterial or venous 
lactate > 4.0 mmol/L within the last hour) 
 
 
Analyses 
 
Primary analysis: 
 
Unadjusted Chi-square test for binary outcome measures. For rate data the 
generalized linear model (SAS proc genmod) will be used with distribution Poisson, link=log and 
offset. 
 
 
Secondary analysis (will only be made for the modified intention-to-treat population): 
 
Multiple (logistic) regression and analysis of rate data with the following covariates: 
 
Binary covariates 
- Center is a university hospital Y/N (stratification variable) 
- Diagnose of hematological malignancy at time of randomisation Y/N 
(stratification variable) 
- Shock at time of randomisation Y/N (as defined above) (stratification 
variable) 
- Diabetes at time of randomisation Y/N 
- Use of nephrotoxic drugs during current admission and prior to 
randomisation Y/N 
- Previous renal dysfunction (‘normal’ creatinine >100 µmol/l = 
baseline variable #2) Y/N 
- Acute Kidney Failure at randomisation (renal failure defining severe 
sepsis as defined above) 
 
Continuous covariate 
- Age 
 
Ordinal covariates 
- SAPS II 
- SOFA-score 
 
 
Outcomes 
 
Primary outcome measure 
The composite outcome measure of 90-day mortality or end-stage kidney disease defined as 
dialysis-dependency 90 days after randomisation (+/- 4 days) as retrieved from the National 
Patient Hospital Register and the National Dialysis Database. 
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These two outcome measures will also be analysed separately. 
 
Secondary outcome measures 
• Twenty-eight-day, 6-month and 1-year mortality 
 
• Time to death or censoring 
 
• SOFA-score without cerebral component (see Appendix 5) on day 5 after randomisation. 
 
• Development of kidney failure defined as 
o Renal component of SOFA-score (renal-SOFA) = 3 or higher at any time in the ICU 
after randomisation, but renal-SOFA < 3 before randomisation (baseline values) 
OR 
o Patient requiring dialysis at any time after randomisation 
 
• Development of kidney failure at any time in the ICU after randomisation defined as 
o Doubling of p-creatinine values = 2 x ‘normal creatinine’ (baseline variable #2) 
 
• Development of acidosis (pHa < 7,35) in the ICU after randomisation 
o As data from day 1 may reflect baseline characteristics, the analysis will be made 
with and without day 1. 
 
• Need of dialysis/haemofiltration at any time after randomisation 
 
• Need of ventilation at any time after randomisation 
 
• Days alive without dialysis/haemofiltration in the 90 days after randomisation 
We define the value of a “period of dialysis” which runs from the day where dialysis is 
initiated till the day where the last dialysis is performed as the number of dates 
included in the period. The outcome measure is calculated as “1 – (the number of 
days in the period of dialysis / the number of days alive in the 90 days follow-up 
period)”. 
 
• Days alive without ventilation in 90 days after randomisation 
If the patient is on the ventilator at 8 am, the day is a ventilator-day. The outcome 
measure is calculated as “1 – (the number of days in ventilator / the number of days 
alive in the 90 days follow-up period)”. 
 
• Days alive and out of hospital in the 90 days after randomisation 
The outcome measure is calculated as “1 – (the number of days in hospital in the 90-
day follow-up period / the number of days alive in the 90-day follow-up period). 
 
• Occurrence of severe bleeding in the ICU defined as clinical bleeding needing three units of 
packed red blood cells or more within 24 hours 
 
• Occurrence of severe allergic reaction in the ICU 
 
 
 
Level of statistical significance for all analyses: P = 0.05 
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Missing Data 
 
Kidney failure at time of randomisation: If the patient doesn’t have kidney failure on day 1, this 
observation will be carried backward. 
 
‘Normal’ creatinine < 100 mmol/l: If the patient has any creatinine < 100 mmol/l without renal 
replacement therapy during or after the ICU-stay, the ‘normal’ creatinine will be considered < 100 
mmol/l.  
 
SOFA-score: There will be missing data for patients who  
- die before day 5 
OR  
- are discharged from the ICU before day 5 and are still alive on day 
5.  
 
Initially, we will perform a complete case-analysis. Then a supplementary analysis 
where patients who die before day 5 get the maximum score (20 points), and here 
patients who are discharged from the ICU and alive on day 5 will get 0 points.  
 
 For patients, who are still in the ICU on day 5, last observation will be carried forward. 
 
SAPS-score: Initiallly, we will perform two analyses where 1) missing SAPS-components in group 
A will be given to the worst possible score AND missing SAPS-components in group 
B will be given the score zero or 2) missing SAPS-components in group A will be 
given the score zero AND missing SAPS-components in group B will be given the 
worst possible score. If there is no difference between these two analyses, we will not 
impute missing data. 
 
If the frequency of missing data after the above implemented “imputations” is > 5% and the 
complete case analysis is significant at the 10% value or less, we will perform an additional 
analysis using the multiple imputation method.  
 
To put significant results into perspective the following sensitivity analysis will be conducted: We 
define a worst case scenario as one where patients with missing data do not react on the 
treatment (whatever it may be). Missing data will be imputed according to this scenario. Let P be 
the estimate of the parameter reflecting the effect of the intervention calculated from the complete 
case analysis and P-imp be the corresponding estimate calculated from the analysis of the 
imputed data.  
[(P-imp – P)/P-imp]*100% then a ball park figure of the bias is to be expected were the worst case 
scenario true. 
P-imp/ (standard error of P-imp) is calculated and the corresponding p value found to assess the 
potential impact of this bias on the significance level.  
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Summary of changes to the Statistical Analysis Plan 
 
 
At the meeting the 5th March 2012 prior to the beginning of the statistical analyses, the following 
changes were made: 
 
- The definitions of rate data (ventilator and dialysis) were corrected.  
 
Dialysis rate = 1 – (the number of days in the period of dialysis / the number of days alive in 
the 90 days follow-up period) 
 
Ventilation rate = 1 – (the number of days in ventilator / the number of days alive in the 90 
days follow-up period) 
 
- We transformed hospital length of stay to a hospital rate. The reason for this is that a very 
high number of patients were readmitted to hospital shortly after discharge and still within 
the 90-day follow-up period. We therefore count the number of days in hospital in the 90-
day follow-up period. The outcome measure is calculated as a rate: 1 – (number of days in 
hospital in the 90-day follow-up period / number of days alive in the 90-day follow-up 
period). 
 
- Occurrence of severe bleeding and occurrence of severe allergic reaction were added to 
the analysis plan as these events must be analysed according to the trial protocol. 
 
- Missingness in the SAPS-score will be assessed as follows: 
SAPS-score: Initiallly, we will perform two analyses where 1) missing SAPS-
components in group A will be given to the worst possible score AND missing SAPS-
components in group B will be given the score zero or 2) missing SAPS-components 
in group A will be given the score zero AND missing SAPS-components in group B 
will be given the worst possible score. If there is no difference between these two 
analyses, we will not impute missing data. 
